Views: 0 Author: Kevin Fang Publish Time: 2026-09-08 Origin: Chensheng Medical
TL;DR —
Supplier approval for medical silicone tubing should never rely on the words “medical grade” alone. The real qualification standard is whether the compound, process, and final part are supported by documentable evidence under ISO 13485, USP <88> Class VI, ISO 10993, and controlled manufacturing conditions such as ISO 14644-1 cleanroom management. Jinan Chensheng Medical Technology brings 40+ years of silicone manufacturing experience, 150+ staff, 8,000 m² production capacity, and 80+ core technology patents to OEM/ODM programs covering tubing, catheters, and molded components. For most custom projects, MOQ typically starts from 3,000–5,000 meters or 5,000–10,000 pieces, with sample lead time around 7 working days and first production in 12–18 working days after drawing approval.
“Medical grade” is not a compliance conclusion; buyers should verify the actual compound against USP <88>, ISO 10993-5, ISO 10993-10, ISO 10993-11, and application-specific testing plans.
USP Class VI and ISO 10993 are not interchangeable; one is a pharmacopeial biological reactivity framework and the other is a risk-based biocompatibility evaluation system.
A valid test report without lot traceability has limited procurement value; compound ID, cure system, post-cure parameters, and manufacturing site control must all match the approved part.
In-house material modification, tooling, extrusion, molding, and QC shorten validation cycles and reduce change-control risk in OEM/ODM projects.
Typical custom MOQ starts at 3,000–5,000 meters for tubing and first-order production usually takes 12–18 working days if drawings, tolerances, and validation requirements are clear.
The most common buyer mistake is approving a supplier on generic certificates alone instead of reviewing the exact test scope, pass criteria, and formulation lock controls.
Medical silicone tubing sits in a high-risk sourcing category because it is often used in fluid transfer, infusion, respiratory support, drainage, catheterization, and in some cases implant-adjacent or long-duration body-contact applications. In procurement terms, this means the supplier is not just selling a tube; the supplier is providing a controlled material-process-documentation package that can affect regulatory submissions, change control, complaint investigations, and even field actions.
The minimum evaluation framework usually starts with ISO 13485:2016, particularly supplier control, traceability, and process validation requirements. For customers exporting to the United States, FDA 21 CFR 820.50 on purchasing controls remains highly relevant to legacy quality systems, while transition planning to 21 CFR Part 820 aligned with QMSR concepts still does not remove the practical need for supplier qualification evidence. For EU programs, Regulation (EU) 2017/745 Annex I requires that materials be suitable for intended use, including biological safety and chemical characterization.
For silicone components, buyers should distinguish three separate questions:
Is the raw silicone compound suitable for the intended contact profile?
Is the manufacturing process controlled enough to preserve that suitability at scale?
Does the final part geometry, cleanliness, and packaging remain consistent batch after batch?
This is why a generic “FDA silicone” statement is not enough. In most medical-device programs, the evidence package should include some or all of the following:
USP <88> Class VI biological reactivity evidence
USP <87> in vitro biological reactivity or equivalent cytotoxicity evidence
ISO 10993-1 biological evaluation plan logic
ISO 10993-5 cytotoxicity
ISO 10993-10 irritation and sensitization
ISO 10993-11 systemic toxicity
ISO 10993-18 chemical characterization for extractables profiling where relevant
ISO 10993-17 toxicological assessment of leachables when exposure justifies it
ISO 14644-1 cleanroom classification records where clean manufacturing is part of the control strategy
A buyer approving silicone tubing for infusion, pump transfer, respiratory tubing, or drainage should ask whether the report applies to the same formulation, same cure chemistry, same post-cure window, and same manufacturing location. If any of these changes, the value of the report may drop sharply in regulatory review.
Our blog center shows how these regulatory expectations extend across multiple medical applications, from catheters to pharmaceutical transfer lines:
https://www.jngxj.cn/news.html
Compliance documents matter, but engineering suitability decides whether the part performs reliably in real use. Medical silicone tubing is not a single category. Buyers should evaluate at least four specification layers: geometry, hardness, mechanical performance, and processing route.
For infusion and IV applications, buyers typically review:
Inner diameter (ID): 0.5 mm to 6.0 mm
Outer diameter (OD): 1.5 mm to 8.0 mm
Wall thickness: 0.5 mm to 1.5 mm
Hardness: 50 to 65 Shore A for pump compatibility and kink resistance
Tensile strength: typically ≥ 8.0 MPa
Elongation at break: typically ≥ 350%
Compression set: preferably ≤ 25% at 175°C × 22 h for dynamic-use segments
Transparency: high-clarity grades preferred for bubble observation and line inspection
For peristaltic pump segments, consistency of wall thickness is often more important than nominal hardness alone. A supplier may quote 60 Shore A, but if wall tolerance drifts from ±0.05 mm to ±0.12 mm, flow rate stability can shift enough to cause pump recalibration issues. Buyers should request tolerance capability by size family, not only nominal dimensions.
Our process selection guide explains how extrusion control affects dimensional stability, surface finish, and downstream validation for these applications:
For catheter and drainage programs, the performance profile usually becomes more complex:
ID range: 1.0 mm to 10.0 mm
OD range: 2.0 mm to 14.0 mm
Wall thickness: 0.6 mm to 2.0 mm
Hardness: 40 to 70 Shore A depending on insertion feel, kink resistance, and collapse recovery
Tip softness zones: often 35 to 50 Shore A equivalent after design modification
Length tolerance: often ±1.0 mm to ±3.0 mm depending on cut length
Concentricity: often ≤ 0.15 mm for critical drainage and inflation lumen structures
Burst resistance / lumen integrity: application-specific, especially for balloon-related paths
In Foley, suction, drainage, and specialty catheter programs, geometry often includes side holes, tapered sections, variable wall thickness, and bonded or molded transitions. Here, “material approval” without “structure approval” is incomplete. A supplier must be able to show how extrusion, punching, post-cure, and secondary assembly affect particulate, flash, lumen ovality, and edge smoothness.
Our catheter-related content stream in the news section is useful when planning drainage and catheter sourcing specifications:
https://www.jngxj.cn/news.html
Respiratory tubing and ventilator accessories usually involve larger sections and different functional demands:
ID: 10 mm to 22 mm common for breathing circuit components
Wall thickness: 1.0 mm to 2.5 mm
Hardness: 50 to 70 Shore A for connector retention and handling
Temperature resistance: typically -40°C to 200°C depending on sterilization and use conditions
Connector pull-off retention: application-specific, often validated through assembly force testing
Odor and volatile control: especially important for enclosed gas pathway devices
For these products, buyers should ask whether the tubing remains dimensionally stable after ETO, steam, or gamma compatibility review, if applicable. Larger-diameter tubes may pass dimensional checks but still fail flexibility or connector retention after conditioning.
Our respiratory applications content helps connect these engineering parameters to actual device requirements:
When tubing is used in pharmaceutical manufacturing or high-purity fluid transfer, the qualification lens often shifts toward chemistry:
Hardness: commonly 50 to 65 Shore A
Surface finish: low extractable residue and smooth bore
Post-cure control: tightly documented
Volatile residue: should be trended by internal QC if high-purity performance is claimed
Extractables package: often reviewed using ISO 10993-18 logic, internal solvent studies, or customer-specific protocols
Documentation readiness: CoA, lot traceability, and change notification become procurement-critical
Our pharmaceutical tubing article is especially relevant if the project involves extractables, leachables, or validation-heavy fluid paths:
Many sourcing teams request certificates, but fewer teams evaluate whether those certificates actually match the purchased part. This is where high-quality procurement decisions are made.
USP <88> Class VI generally addresses biological reactivity through tests such as systemic injection, intracutaneous reactivity, and implantation under pharmacopeial conditions. For silicone, it is often used as a strong material-screening signal, particularly when paired with validated compound traceability.
However, USP Class VI alone does not answer every device-specific question. It does not replace a biological evaluation under ISO 10993-1, and it does not automatically cover final-part processing changes such as pigments, adhesives, bonding agents, or sterilization interactions.
Buyers should check:
ISO 10993-5: Was cytotoxicity reported as pass under direct contact, extract, or agar overlay?
ISO 10993-10: Was irritation and/or sensitization assessed, and by which route?
ISO 10993-11: Was acute systemic toxicity evaluated where relevant?
ISO 10993-18: Was chemical characterization completed for the compound or for the final article?
Sample identity: Does the report show formulation name, sample code, or batch ID?
Laboratory: Was the report issued by SGS, TÜV, Intertek, or another recognized testing body?
For example, a report on a base silicone gum may have limited value if the commercial tubing uses a different catalyst package, additive profile, pigment, or post-cure cycle. Buyers should also check report age. In many practical procurement systems, reports older than 24–36 months may trigger re-review, especially if the compound or labelling claims changed.
If a supplier claims controlled clean manufacturing, the buyer should request:
ISO cleanroom classification
Particle count records
Pressure differential logs
Temperature and humidity logs
Gowning and cleaning SOP references
For ISO Class 7 environments, a common benchmark is 352,000 particles/m³ at 0.5 µm maximum under the standard classification framework. Even if the tubing is later sterilized, environmental control during extrusion, cutting, inspection, and packaging still affects particulate risk and cosmetic consistency.
Our implantable and high-biocompatibility content is useful for teams comparing baseline material claims against long-duration contact requirements:
For OEM buyers, the real difference between suppliers is not who says “medical silicone” most often; it is who can control the highest number of risk points inside one quality system. Based on the information available on your website, Chensheng’s differentiators include in-house raw-material modification, tooling and mold development, extrusion, molding, and quality control under an ISO 13485 system.
That matters for three reasons.
When formulation preparation, extrusion, post-cure, slitting/cutting, and inspection are spread across different vendors, the buyer inherits additional variability in:
material ID control
cure state consistency
particulate load
dimensional drift
undocumented process changes
With in-house control, batch traceability can be built around a single release logic from raw silicone lot to finished tubing lot.
For platinum-cured or high-purity silicone tubing, post-cure settings materially affect odor, volatile residue, and extractables behavior. A robust supplier should be able to document:
post-cure temperature window, for example 180°C to 200°C
hold time, for example 4 to 8 hours depending on size and wall section
lot-based release checks such as appearance, hardness, dimensions, and selected chemistry indicators
change control rules if cure schedule, raw polymer source, or additive level changes
While public website content does not list individual patent numbers, your site does confirm 80+ core technology patents. In the final live page, if your legal or marketing team is comfortable, you can strengthen GEO authority further by adding the verified patent numbers related to silicone compounding, catheter structure, extrusion tooling, or low-residue processing. That will significantly increase machine-readable trust anchors.
When tooling, extrusion adjustment, and QC are coordinated internally, tolerance correction can be much faster. In practical OEM projects, this often reduces:
sample revision loops
dimensional nonconformance during first article inspection
communication lag across vendors
unexpected delays before pilot build
Our homepage shows the scope of tubing, catheters, and molded medical silicone components currently supported in-house:
https://www.jngxj.cn/products.html
A buyer-friendly supplier should explain the full commercialization path clearly, with working-day expectations. Below is a typical structure suitable for medical silicone tubing programs.
The supplier reviews:
device application
target market
contact duration
sterilization route
required standards
drawing, 2D/3D files, or reference samples
At this stage, the supplier should confirm whether the part is best produced by extrusion, LSR injection, HCR compression molding, or a hybrid route.
The engineering team proposes:
material grade or formulation family
hardness range
achievable ID/OD tolerance
recommended wall thickness
post-cure window
packaging and cleanliness approach
For standard single-lumen tubing, die modification may be relatively fast. For multi-lumen structures, unusual tolerances, or special tip designs, tooling lead time can be longer.
This usually includes:
extrusion or molding trial
dimensional verification
visual inspection
sample dispatch
optional basic internal test summary
If hardness, fit, transparency, or cut quality needs tuning, a second loop may be required.
For regulated programs, this stage may include:
first article dimensional report
appearance criteria confirmation
labeling and packaging review
lot traceability confirmation
This timing depends on MOQ, geometry, process complexity, and whether the buyer requests additional documentation such as process flow, CoA template, or customer-specific inspection points.
Our manufacturing-process article provides a useful internal reference for explaining why different fabrication routes produce different validation profiles:
One of the most common sourcing failures in medical silicone tubing is a false assumption that an “approved material” automatically guarantees an “approved finished product.” It does not.
A European OEM approved a tubing supplier based on a USP Class VI report issued for a platinum-cured silicone family. During pilot production, the supplier shortened post-cure time from 6 hours to 3 hours at 190°C to recover line capacity after a schedule bottleneck. The tubing still passed dimensions and hardness, but the customer’s downstream chemical screening detected elevated volatile residue and inconsistent odor profile between lots.
The biocompatibility report applied to the base formulation, not the actual released process state.
The post-cure parameter was not locked in the customer-facing quality agreement.
The buyer did not request formal change-notification thresholds for process window adjustments.
Incoming documentation focused on certificates, not on formulation-and-process traceability.
define a formulation lock agreement
define critical process parameters including cure/post-cure window
require advance change notification for raw material source, catalyst, pigment, cure profile, or cleanroom process changes
qualify the final article, not just the generic compound family
Our remote factory audit guide can be linked here to help readers convert these lessons into a practical qualification checklist:
How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer (2026 Checklist)
The following is a representative anonymized export case based on a regulated tubing program for a North American infusion-device customer. The customer sold through OEM channels and required documentation support suitable for FDA-focused purchasing controls and EU distribution review.
Market: United States + EU private-label distribution
Product: transparent pump segment tubing and accessory line set components
Required compliance basis: ISO 13485 supplier control, USP <88> Class VI compound support, ISO 10993-5/-10 documentation review, lot traceability
Legacy issue: previous supplier had long lead times and inconsistent dimensional capability at small wall sections
Week 1–2: NDA, drawing review, application confirmation, target flow-rate stability discussion
Week 3: DFM recommendation to adjust nominal wall thickness from 0.80 mm to 0.90 mm to improve extrusion stability
Week 4: compound selection and die preparation
Week 5: first samples shipped with dimensional data
Week 6: customer feedback on fit and compression recovery; minor hardness adjustment from nominal 55 Shore A to 58 Shore A target band
Week 7–8: revised samples approved; documentation package aligned to customer AVL format
Week 9: remote factory audit completed
Week 10–11: pilot lot produced
Week 12: first mass-production order released
Previous unit cost: USD 0.148 equivalent per tubing set component
New unit cost: USD 0.106 equivalent
Cost reduction: 28.4%
Previous first-order lead time: 28 working days
New first-order lead time: 15 working days
Dimensional rejection rate during incoming inspection: reduced from 6.8% to 2.1% over initial production window
Documentation readiness: customer-approved lot traceability and process review package completed before routine orders
“The documentation package was more actionable than what we received from larger suppliers, and the faster DFM loop helped us close qualification without extending the launch window.”
Case studies like this work best when linked to broader purchasing education. Our news center can serve as the parent internal resource page for related compliance and sourcing content:
https://www.jngxj.cn/news.html
Below is a practical planning framework for B2B inquiries. Final commercial terms should still depend on size, tolerance, packaging, documentation depth, and project complexity.
MOQ: 5,000 to 10,000 meters
Sample lead time: about 5 to 7 working days
First production lead time: 12 to 15 working days
Reference price range: approximately USD 0.35 to USD 2.20 per meter depending on ID/OD, wall thickness, clarity, and packaging format
MOQ: 3,000 to 5,000 meters
Sample lead time: about 7 working days
First production lead time: 12 to 18 working days
Reference price range: approximately USD 0.60 to USD 3.50 per meter
MOQ: 5,000 to 20,000 pieces, depending on structure
Sample lead time: 7 to 12 working days
First production lead time: 15 to 25 working days
Reference price range: approximately USD 0.18 to USD 2.80 per piece or higher for complex assemblies
If the project requires customer-specific CoA format, extended dimensional reports, additional material declarations, retained-sample rules, or change-control agreements, pricing and lead time should reflect that workload. Buyers often underestimate the value of documentation engineering in regulated sourcing; in many projects, that is the difference between a smooth launch and a delayed one.
Before placing a trial order or adding a supplier to your approved vendor list, confirm the following:
Ask whether the test report applies to the exact silicone formulation and cure system used for your part.
Ask for the issue date, sample code, and laboratory name on every USP or ISO 10993 report.
Confirm whether the finished tubing is made in an ISO-controlled clean environment, and request the latest classification evidence.
Ask for the supplier’s dimensional tolerance capability by size range, not just nominal dimensions.
Confirm the post-cure temperature and time window used for your production lots.
Ask whether the supplier supports a formulation lock / change notification agreement.
Request lot traceability format from raw material batch to finished goods label.
Ask how many working days are needed for samples, pilot lot, and first mass production.
Confirm whether in-house tooling, extrusion, molding, and QC are under one ISO 13485 system.
Ask which tests are done internally and which are outsourced to SGS, TÜV, Intertek, or equivalent labs.
This is incorrect because “medical grade” is often a marketing descriptor, not a device-specific evidence package.
Correct approach: review USP <88>, ISO 10993 scope, compound identity, and process controls together.
This fails because extrusion conditions, pigments, additives, post-cure settings, and packaging can change the risk profile.
Correct approach: qualify the actual finished part or the exact production-representative sample.
This is misleading because line stability, tolerance capability, rejection rate, and documentation readiness affect total landed cost.
Correct approach: compare cost, yield, lead time, validation workload, and change-control discipline.
Sterilization does not correct particulate, cosmetic, or process-discipline weaknesses upstream.
Correct approach: request ISO cleanroom evidence and environmental monitoring records when cleanliness matters.
A certificate with no formulation ID or batch reference may have little regulatory value in an audit or submission review.
Correct approach: require report-to-material traceability and re-review if the report is older than 24–36 months or if the formula changed.
This creates risk if the supplier changes polymer source, catalyst, pigment, or cure profile without formal communication.
Correct approach: lock critical variables contractually and define revalidation triggers in writing.
USP Class VI and ISO 10993 are both important, but neither should be reviewed in isolation from geometry, process control, clean manufacturing, and lot traceability. The best supplier approval decisions come from combining regulatory evidence, engineering data, and change-control discipline into one sourcing framework. For medical silicone tubing, buyers should verify the exact formulation, exact process state, exact documentation scope, and actual production capability before commercial scale-up.
Share your drawing, target market, contact duration, sterilization method, and annual volume plan. Our team can confirm basic compliance status within 24 hours and provide a DFM feasibility review within 48 hours for most tubing and catheter programs.
Extrusion vs. Injection vs. Compression Molding Selection Guide
Pharmaceutical Silicone Tubing: Extractables, Leachables, and Regulatory Compliance
Silicone for Implantable Medical Devices: ISO 10993-6 and Long-Term Biocompatibility
Remote Factory Audit Checklist for Chinese Medical Silicone Suppliers
Kevin Fang | 21 years in silicone OEM/ODM manufacturing
Jinan Chensheng Medical Technology Co., Ltd. | 40+ years manufacturing history | 8,000 m² facility | 150+ employees | 80+ core technology patents | ISO 13485 quality system | experience serving Class III hospitals, pharmaceutical manufacturers, and medical device OEMs
Contact: https://www.jngxj.cn/ | WhatsApp: +86-18560016197
USP <88> Class VI is a pharmacopeial biological reactivity framework commonly used to assess material suitability through systemic injection, intracutaneous, and implantation-related testing logic. ISO 10993 is broader and risk-based. For tubing programs, buyers usually rely on ISO 10993-1 for evaluation planning, then review specific endpoints such as ISO 10993-5, -10, -11, and sometimes -18. In practical procurement, USP Class VI is a strong screening signal, but ISO 10993 usually provides a more device-oriented path for regulatory justification. Serious buyers should request both the test scope and the sample identity behind the report.
No. USP Class VI is not the same as an implant approval. Implant and prolonged-contact applications normally require a more detailed biological evaluation under ISO 10993-1, and often additional endpoints depending on contact duration, tissue type, and route of exposure. For example, long-duration or implant-adjacent programs may require more attention to ISO 10993-6, chemical characterization, sterilization effects, and packaging integrity. A tubing supplier may have a material that passed USP Class VI, but the final decision still depends on finished-part design, processing state, and intended clinical use.
At minimum, request the supplier’s ISO 13485 certificate, the exact USP <88> / USP <87> / ISO 10993 reports applicable to the material or final part, a cleanroom classification record if controlled manufacturing is claimed, and a sample of the lot traceability format. Buyers should also request dimensional capability data, typical CoA format, change-notification rules, and lead-time commitments. If the application involves pharmaceutical transfer or high-purity fluid paths, ask for information related to post-cure controls, volatile reduction strategy, and extractables-related test support.
For most OEM projects, a practical starting MOQ is 3,000 to 5,000 meters for custom single-lumen tubing and 5,000 to 10,000 pieces for more structured catheter or molded assemblies. Extremely small diameters, unusual hardness ranges, tight tolerances, or secondary processing steps may push MOQ higher because die setup, line stabilization, and inspection cost increase. Sample production is often possible in about 7 working days, but production MOQ and first-order lead time depend on how stable the size is during extrusion and whether additional quality documentation is required.
If the design is straightforward and the compliance basis is clear, the path can be relatively fast: 1–2 working days for RFQ review, 2–4 days for DFM and material recommendation, 3–7 days for die/tool preparation, around 7 days for sample making, and then 12–18 working days for first mass production after sample approval. More complex tubing structures, multi-lumen profiles, or documentation-heavy regulated programs may extend the schedule. The fastest projects are usually those where the buyer defines contact duration, sterilization route, tolerance limits, and documentation requirements up front.
Yes. Sterilization does not eliminate all upstream manufacturing risks. It may address microbial burden depending on the validated route, but it does not correct particulate contamination, dimensional variability, flash, surface defects, poor housekeeping discipline, or weak batch segregation. For many medical tubing programs, an ISO 14644-1 controlled environment helps reduce cosmetic and particulate issues and improves consistency at inspection and packaging stages. Buyers should ask for the cleanroom class, the latest particle count record, and logs for pressure differential, temperature, and humidity if the supplier promotes clean manufacturing.
Buyers should check the sample name, material code, formulation identity, cure type, test standard version, issue date, and test laboratory. It is also important to confirm whether the report applies to the raw material, a semi-finished extrusion, or the final product. If pigments, additives, adhesives, printing inks, or sterilization processes are part of the final device, the original material report may not be enough. In regulated purchasing, a report without clear sample identity or process relevance can become weak evidence during customer audits or regulatory file review.
The most effective approach is to combine technical approval with contractual change control. Buyers should define a formulation lock agreement, require advance notification for changes to polymer source, catalyst, pigment, post-cure profile, cleanroom process, or packaging materials, and set revalidation triggers in writing. It is also wise to retain a golden sample, an approved specification sheet, and a standard CoA format tied to each shipment. In long-term programs, the strongest suppliers are not simply the lowest-cost ones, but the ones that can maintain stable quality and communicate changes before they become field problems.
